Stinchcombe TE, Jänne PA, Wang X, et al. - Given that erlotinib offers a median progression-free survival (PFS) of approximately 10 months in patients with epidermal growth factor receptor (EGFR)–mutant non–small cell lung cancer (NSCLC), researchers focused on PFS in relation to the addition of bevacizumab to erlotinib treatment vs erlotinib alone in this phase II randomized clinical trial run in 17 US academic and community medical centers. Participants (n = 88) were eligible for bevacizumab, had stage 4 NSCLC, and had EGFR exon 19 deletion or exon 21 L858R mutation based on local testing. In a randomized manner, the patients were equally assigned to 150 mg of oral erlotinib daily alone or with 15 mg/kg of intravenous bevacizumab every 3 weeks. Findings revealed no significant improvement in PFS in correlation with erlotinib plus bevacizumab vs erlotinib alone treatment in patients with EGFR-mutant NSCLC.